Projects
This section presents pharmaceutical projects that are announced from time-to-time around the world.
TriLink BioTechnologies to Open Drug Production Facility in USA
TriLink BioTechnologies plans to open a stateoftheart facility dedicated to latephase mRNA drug substance production in the United States
Fujifilm Invests US$1.2 billion to Expand Manufacturing Facility in USA
Fujifilm plans to invest US$12 billion to open stateoftheart manufacturing hubs in the United States The expansion will significantly enhance the largescale production
Almac Group Invests US$540 million (£400mn) to Expand Production Capacity in Ireland
Almac Group invests US$540 million 400mn for the completion of two new purposebuilt facilities at Ireland
Sandoz Plans to Open New Production Facility in Austria, Europe
Sandoz plans to open a new antibiotic production facility in Austria, Europe This stateoftheart facility will boost the production capacity for crucial lifesaving medicines
Novartis Invests US$541 million (€500 million) in Austria, Europe
Novartis is investing US$541 million 500 million to open new biopharmaceutical production in Austria To enhance production capabilities through innovative initiatives
Abzena Invests US$5 million to Expands its Manufacturing Site in Pennsylvania, USA
Abzena invests US$5 million to expand its bioconjugate development and cGMP manufacturing site in Pennsylvania, USA The investment in expanding laboratory space, acquiring new equipment
Syngene Biologics Invests US$98 million for Upgrading Manufacturing Facility in India
Syngene Biologics plans to invest US$98 million to open newly upgraded biologics facility in Bangalore, India The new facility with two production suites, each housing with 2KL
Aptar Pharma Expands its Manufacturing Capacity in New York, USA
Aptar Pharma plans to expand its manufacturing capacity and capabilities in New York, USA This expansion involves a building extension
SK bioscience Expands its Vaccine Manufacturing Facility in Andong, South Korea
SK bioscience plans to expand its vaccine manufacturing facility in Andong, South Korea The expansion enhances manufacturing capabilities for global supply by extending the vaccine
Merck Invests US$324 million (€300 mn) in Daejeon, South Korea
Merck plans to invest US$324 million 300 mn to open new bioprocessing production centre for the development of biologics in Daejeon, South Korea
